GlassScriptPhysician profile
Shaun L'Esperance
NPI 1386036457
$1,342.36
in general payments reported to CMS, 2019-2025
13 companies · $745 in 2025
The $745 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $75.65 · 2023: $191 · 2024: $330 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $148.11 | 2025 | |
| Madrigal Pharmaceuticals | $132.33 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $125.00 | 2025 | |
| Amgen INC. | $121.84 | 2025 | Tepezza |
| Alexion Pharmaceuticals, INC. | $121.58 | 2025 | Koselugo |
| Astrazeneca Pharmaceuticals LP | $99.12 | 2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $96.51 | 2025 | |
| Sage Therapeutics, LLC | $96.45 | 2023 | |
| Gilead Sciences, INC. | $94.45 | 2023 | Epclusa |
| Astellas Pharma US INC | $85.50 | 2024 | Veozah |
| Viiv Healthcare Company | $76.11 | 2024 | Apretude |
| Novo Nordisk INC | $75.65 | 2022 | |
| Inspire Medical Systems, INC. | $69.71 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun L'Esperance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.